Parkinson's Disease in a Chemist Working with 1-Methyl-4-Phenyl-L,2,5,6-Tetrahydropyridine
- 4 August 1983
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 309 (5), 310
- https://doi.org/10.1056/nejm198308043090511
Abstract
To the Editor: We have recently reported that in patients receiving 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) intravenously all the classic features of Parkinson's disease develop.1 , 2 This phenomenon appears to result from selective cell damage in the substantia nigra — a finding that has now been confirmed in primates.3 To date, all patients experiencing these tragic complications of exposure to MPTP have received the substance intravenously.2 , 4 We now report a case of Parkinson's disease in a person who was exposed to MPTP but who never received the substance intravenously.A 49-year-old chemist began working in 1964 for a major pharmaceutical company. During the next . . .Keywords
This publication has 3 references indexed in Scilit:
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979
- PIPERIDINE DERIVATIVES. PART III. 4-ARYLPIPERIDINES1The Journal of Organic Chemistry, 1947